Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Astellas Pharma

Evaluate

Thumbnail
July 31, 2023

ASRS 2023 – Syfovre’s side-effect questions still loom large

Thumbnail
July 28, 2023

Go or no go? Biogen and Astellas head towards key Pdufas

Article image
Vantage logo
July 26, 2023

GSK admits anaemia defeat

Article image
Vantage logo
July 14, 2023

Acadia pays $100m to double up in Rett

Article image
Vantage logo
July 04, 2023

Biopharma buyouts bounce back

Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.

Article image
Vantage logo
June 27, 2023

Pamrevlumab’s second misfire leaves Fibrogen short of options

Article image
Vantage logo
June 23, 2023

Amylyx rebuff sees Europe regulators diverge from the US

Article image
Vantage logo
June 09, 2023

Asco 2023 story roundup

Article image
Vantage logo
June 03, 2023

Asco 2023 – Elevation follows in Astellas’s slipstream

There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.

Article image
Vantage logo
June 01, 2023

US FDA approval and panel tracker: May 2023

Article image
Vantage logo
May 30, 2023

Asco 2023 preview – a microcap winner

One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up